1. Top of page
  2. Abstract

Peptides of the glucagon/vasoactive-intestinal-peptide (VIP) peptide family share a considerable sequence similarity at their N-terminus. They either start with Tyr-Ala, His-Ala or His-Ser which might be in part potential targets for dipeptidyl-peptidase IV, a highly specialized aminopeptidase removing dipeptides only from peptides with N-terminal penultimate proline or alanine. Growthhormone-releasing factor(1–29)amide and gastric inhibitory peptide/glucose-dependent insulinotropic peptide (GIP) with terminal Tyr-Ala as well as glucagon-like peptide-1(7–36)amide/insulinotropin [GLP-1(7–36)amide] and peptide histidine methionine (PHM) with terminal His-Ala were hydrolysed to their des-Xaa-Ala derivatives by dipeptidyl-peptidase IV purified from human placenta. VIP with terminal His-Ser was not significantly degraded by the peptidase. The kinetics of the hydrolysis of GIP, GLP-1(7–36)amide and PHM were analyzed in detail. For these peptides Km values of 4–34 μM and Vmax values of 0.6–3.8 μmol · min−1· mg protein−1 were determined for the purified peptidase which should allow their enzymic degradation also at physiological, nanomolar concentrations. When human serum was incubated with GIP or GLP-1(7–36)amide the same fragments as with the purified dipeptidyl-peptidase IV, namely the des-Xaa-Ala peptides and Tyr-Ala in the case of GIP or His-Ala in the case of GLP-1(7–36)amide, were identified as the main degradation products of these peptide hormones. Incorporation of inhibitors specific for dipeptidylpeptidase IV, 1 mM Lys-pyrrolidide or 0.1 mM diprotin A (Ile-Pro-Ilc), completely abolished the production of these fragments by serum. It is concluded that dipeptidyl-peptidase IV initiates the metabolism of GIP and GLP-1(7–36)amide in human serum. Since an intact N-terminus is obligate for the biological activity of the members of the glucagon/VIP peptide family [e. g. GIP(3–42) is known to be inactive to release insulin in the presence of glucose as does intact GIP], dipeptidyl-peptidase-IV action inactivates these peptide hormones. The relevance of this finding for their inactivation and their determination by immunoassays is discussed.


dipeptidyl-peptidase IV


gastric inhibitory polypeptide or glucose-dependent insulinotropic polypeptide


glucagon-like peptide-1(7–36)amide or insulinotropin or preproglucagon(78–107)amide


glucagon like peptide-2 or preproglucagon(126–159)


growth-hormone-releasing factor/hormone


peptide histidine isoleucine


peptide histidine methionine


vasoactive intestinal peptide


pituitary adenylate-cyclase-activating polypeptide


Dipeptidyl peptidase IV (EC


  1. Top of page
  2. Abstract
  • Ahmad, S., Wang, L. & Ward, E. (1992) Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo, J. Pharm. Exp. Ther. 260, 12571261.
  • Boden, G. & Shelmet, J. J. (1986) Gastrointestinal hormones and carcinoid tumors and syndrome in Endocrinology and metabolism (Felig, P., Baxter, J. D., Broadus, A. E. & Frohman, L. A., eds) pp. 16291662, McGraw-Hill, New York .
  • Bongers, J., Lambros, T., Ahmad, M. & Heimer, E. P. (1992) Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs, Biochim. Biophys. Acta 1122, 147153.
  • Boulanger, L., Roughly, P. & Gaudreau, P. (1992) Catabolism of rat growth hormone-releasing factor(1–29)amide in rat serum and liver, Peptides (Elmsford) 13, 681689.
  • Buckley, D. I. & Lundquist, P. (1992) Analysis of the degradation of insulinotropin [GLP-1(7–37)] in human plasma and production of degradation resistant analogs, Regul. Peptides 40, 117.
  • Christophe, J., Svoboda, M., Dehaye, J.-P., Winand, J., Vander-meers-Pire, M.-C., Vandermeers, A., Cauvin, A., Gourlet, P. & Robberecht, P. (1989) The VIP/PHI/secretin/helodermin/helospectin/GRF family: structure-function relationship of the natural peptides, their precursors and synthetic analogues as tested in vitro on receptors and adenylate cyclase in a panel of tissue membranes, in Peptide hormones as prohormones: processing, biological activity, pharmacology (Martinez, J., ed.) pp. 211243, Ellis Horwood LTD, Chichester .
  • Frohman, L. A., Downs, T. R., Heimer, E. P. & Felix, A. M. (1989) Dipeptidyl peptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma, J. Clin. Invest. 83, 15331540.
  • Gallwitz, B., Schmidt, W. E., Conlon, J. M. & Creutzfeldt, W. (1990) Glucagon-like peptide-1 (7–36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells, J. Mol. Endocrinol. 5, 3339.
  • Gossrau, R. (1979) Zur Lokalisation der Dipeptidylpeptidase IV (DPP IV). Histochemische und biochemische Untersuchungen, Histochemistry 60, 231248.
  • Hartel, S., Gossrau, R., Hanski, C. & Reutter, W. (1988) Dipeptidyl peptidase IV in rat organs. Comparison of immunohistochemistry and activity histochemistry, Histochemistry 89, 151161.
  • Heins, J., Welker, P., Schönlein, C., Born, I., Hardtrodt, B., Neubert, K., Tsuru, D. & Barth, A. (1988) Mechanism of proline-specific proteinases: (I) substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum, Biochim. Biophys. Acta 954, 161169.
  • Heymann, E. & Mentlein, R. (1978) Liver dipeptidyl peptidase IV hydrolyzes substance P, FEBS Lett. 91, 360364.
  • Jörnvall, H., Carlquist, M., Kwauk, S., Otte, S. C., McIntosch, C. H. S., Brown, J. C. & Mutt, V. (1981) Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP), FEBS Lett. 123, 205210.
  • Kubiak, T. M., Kelly, C. R. & Krabill, L. F. (1989) In vitro metabolic degradation of a bovine growth hormone-releasing factor analog Leu27-bGRF(1–29)NH2 in bovine and porcine plasma, Drug. Metab. Dispos. 17, 393397.
  • Loijda, Z. (1979) Studies on dipeptidyl(amino)peptidase IV. II. Blood vessels, Histochemistry 59, 153166.
  • McCaughan, G. W., Wickson, J. E., Cheswick, P. F. & Gorrell, M. D. (1990) Identification of the bile canicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: an analysis by tissue distribution, purification and N-terminal amino acid sequence, Hepatology 11, 534544.
  • Mentlein, R. (1988) Proline residues in the maturation and degradation of peptide hormones and neuropeptides, FEBS Lett. 234, 251256.
  • Mentlein, R., Heymann, E., Scholz, W., Feller, A. C. & Flad, H.-D. (1984) Dipeptidyl peptidase IV as a new surface marker for a subpopulation of human T-lymphocytes, Cell. Immunol. 89, 1119.
  • Mentlein, R. & Struckhoff, G. (1989) Purification of two dipeptidyl aminopeptidases II from rat brain and their action on prolinecontaining neuropeptides, J. Neurochem. 52, 12841293.
  • Nausch, I. & Heymann, E. (1985) Substance P in human plasma is degraded by dipeptidyl peptidase IV, not by cholinesterase, J. Neurochem. 44, 13541357.
  • Nausch, I., Mentlein, R. & Heymann, E. (1990) The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta, Biol. Chem. Hoppe-Seyler 371, 11131118.
  • Püschel, G., Mentlein, R. & Heymann, E. (1982) Isolation and characterization of dipeptidyl peptidase IV from human placenta, Eur. J. Biochem. 126, 359365.
  • Rahfeld, J., Schierhorn, M., Hartrodt, B., Neubert, K. & Heins, J. (1991a) Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates for dipeptidyl peptidase IV? Biochim. Biophys. Acta 1076, 314316.
  • Rahfeld, J., Schutkowski, M., Faust, J., Neubert, K., Barth, A. & Heins, J. (1991b) Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney, Biol. Chem. Hoppe-Seyler 372, 313318.
  • Robberecht, P., Cauvin, A., Gourlet, P. & Christophe, J. (1990) Heterogeneity of VIP receptors, Arch. Int. Pharmacodyn. 303, 5166.
  • Robberecht, P., Gourlet, P., De Neef, P., Woussen-Colle, M.-C., Vandermeers-Piret, M.-C., Vandermeers, A. & Christophe, J. (1992) Structural requirements for the occupancy of pituitary adenylate-cyclase-activating peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes, Eur. J. Biochem. 207, 239246.
  • Schmidt, W. E., Siegel, E. G., Kümmel, H., Gallwitz, B. & Creutzfeldt, W. (1987) Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39, Endocrinology 120, 835837.
  • Schmidt, W. E., Siegel, E. G., Ebert, R. & Creutzfeldt, W. (1986) N-terminal tyrosine-alanine is required for the insulin-releasing activity of glucose- dependent insulinotropic polypeptide (GIP), Eur. J. Clin. Invest. 16, A9.
  • Schutkowski, M. (1991) Untersuchungen zur Substratspezifität prolinspezifischer Peptidasen, Thesis, Martin-Luther-Universität Halle-Wittenberg.
  • Stocchi, V., Cucchiarini, L., Piccoli, G. & Magnai, M. (1985) Complete high-performance liquid chromatographic separation of 4-N,N-dimethylamino-azobenzene-4′-thiohydantoin and 4-dimethylaminoazobenzene-4′-sulphonyl chloride amino acids using the same reverse-phase column at room temperature, J. Chromatogr. 319, 7789.
  • Unson, C. G., Gurzenda, E. M., Iwasa, K. & Merrifield, R. B. (1989) Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1–5, position 12, and the putative α-helical segment 19–27, J. Biol. Chem. 264, 789794.
  • Wilkinson, G. N. (1961) Statistical estimations in enzyme kinetics, Biochem. J. 80, 324332.
  • Wittmann-Liebold, B., Hirano, H. & Kimura, M. (1986) Manual microsequence determination of proteins and peptides with the DABITIC/PITC method, in Advanced methods in protein microsequence analysis (Wittmann-Liebold, B., Salnikow, J. & Erdmann, V. A., eds) pp. 7790, Springer-Verlag, Berlin Heidelberg .